Cryoglobulins and cold agglutinins cause microvascular occlusion
Reversible with rewarming
Therapeutic Considerations
Evidence base for treatment
Conservative therapy produces complete response in approximately 82% of patients
Passive rewarming, protection, smoking cessation most effective interventions
Primary pernio typically resolves within 1 to 3 weeks
Nifedipine evidence
Older RCT by Rustin 1989 demonstrated benefit for pain reduction and healing
Newer RCT by Souwer 2016 found no superiority over placebo for chronic chilblains
Net clinical recommendation: reasonable to offer for moderate to severe or recurrent cases when benefits outweigh uncertain evidence
Emerging evidence for secondary pernio management
Tadalafil and fluoxetine show promise with limited study
Hydroxychloroquine established for chilblain lupus
Prevention strategy
Protective clothing and footwear
Insulated, moisture-wicking socks
Waterproof footwear in wet conditions
Avoid tight footwear that restricts circulation
Lifestyle modification
Smoking cessation primary recommendation
Adequate caloric intake and healthy body weight
Minimize prolonged cold-wet exposure
Prophylactic vasodilator therapy for recurrent primary pernio
Seasonal prophylaxis with nifedipine in high-frequency recurrence
Begin prior to cold season onset
Prognosis
Primary pernio: excellent prognosis with appropriate management
Resolution expected within 1 to 3 weeks
Recurrence with each cold season is common
Secondary pernio prognosis tied to underlying disease
Chilblain lupus may follow relapsing-remitting course
Hematologic malignancy prognosis dependent on type and stage
Patient Discharge Instructions
copy discharge instructions
What are chilblains
Chilblains (pernio) are small, itchy, painful inflammatory spots on the skin
Caused by an abnormal reaction to cold and damp weather
Not frostbite — skin does not freeze
Most cases heal completely within 1 to 3 weeks
Affected areas
Typically toes and fingers
Can also affect ears, nose, or shins
Home care instructions
Warming and skin care
Warm the affected area slowly — avoid sudden heat (hot water bottles, heating pads directly on skin)
Keep skin clean, dry, and covered
Elevate affected feet or hands to reduce swelling
Medications at home
Take pain medicine as prescribed (ibuprofen or acetaminophen)
Apply prescribed topical cream to affected areas as directed
Take any prescribed blood pressure or other medications exactly as directed
Prevention
Wear warm, insulated, waterproof socks, gloves, and footwear in cold or wet weather
Avoid tight footwear that restricts blood flow
Stay warm and dry — limit time outdoors in cold, wet conditions
Stop smoking — smoking makes chilblains worse by reducing blood flow
Maintain healthy nutrition and body weight
What to expect
Healing timeline
Most chilblains heal within 1 to 3 weeks with proper care
Itching and burning may worsen briefly when skin warms up — this is normal
Follow-up appointment
See your family doctor or skin specialist in 2 to 3 weeks
Blood tests may be needed if lesions do not heal by spring or summer
Return to the emergency room immediately if
Skin is turning black, dark purple, or large blisters develop
Increasing pain, spreading redness, warmth, or pus — signs of infection
Fever or chills develop
Loss of feeling (numbness) in affected area
Lesions are not improving or are getting worse despite home care
Lesions persist beyond the cold season (into spring or summer)
New symptoms develop such as joint pain, rash on face, mouth sores, or unusual fatigue
References
Guidelines and key sources
Primary clinical references
Cappel JA, Wetter DA. Clinical Characteristics, Etiologic Associations, Laboratory Findings, Treatment, and Proposal of Diagnostic Criteria of Pernio (Chilblains) in a Series of 104 Patients at Mayo Clinic, 2000 to 2011. Mayo Clinic Proceedings. 2014
PMID 24485134
Foundational epidemiologic and diagnostic reference
Rustin MH, Newton JA, Smith NP, Dowd PM. The Treatment of Chilblains With Nifedipine. British Journal of Dermatology. 1989
PMID 2647123
Older RCT supporting nifedipine efficacy
Souwer IH, Bor JH, Smits P, Lagro-Janssen AL. Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial. Annals of Family Medicine. 2016
PMID 27621162
Newer RCT showing no superiority of nifedipine over placebo
Cold injury and wilderness medicine
Zafren K et al. Prevention and Treatment of Nonfreezing Cold Injuries and Warm Water Immersion Tissue Injuries: A Supplement to the Wilderness Medical Society Clinical Practice Guidelines. Wilderness and Environmental Medicine. 2023
Conservative rewarming and supportive care protocols
CDC Yellow Book. Heat and Cold Illness in Travelers. Howard D. Backer and Luanne Freer. 2025
Traveler context cold injury classification and management
COVID-19 associated pernio
Hubiche T et al. Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic. JAMA Dermatology. 2021
Pathophysiology and interferon-alpha mechanism
McCleskey PE et al. Epidemiologic Analysis of Chilblains Cohorts Before and During the COVID-19 Pandemic. JAMA Dermatology. 2021
Pandemic surge epidemiology
Cappel MA, Cappel JA, Wetter DA. Pernio (Chilblains), SARS-CoV-2, and COVID Toes Unified Through Cutaneous and Systemic Mechanisms. Mayo Clinic Proceedings. 2021
PMID 33714595
Unifying mechanistic framework for COVID toes
Secondary pernio and autoimmune references
Sharifzadeh A, Smith GP. An Evidence-Based Review of Perniosis (Chilblains): Therapeutic Strategies and Integration With Raynaud's Syndrome Management. International Journal of Dermatology. 2025
PMID 40272049
Current therapeutic review including emerging agents
Joshi N et al. Novel Association of Chilblains With Inflammatory Arthritis. Rheumatology International. 2025
Diagnostic and management framework for lupus-associated secondary pernio
Pediatric reference
Simon TD, Soep JB, Hollister JR. Pernio in Pediatrics. Pediatrics. 2005
PMID 16140694
Pediatric epidemiology and anorexia nervosa association
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.